论文部分内容阅读
With a diverse range of mitochondrial targeted drugs currently in clinical trials,targeting mitochondria as a cancer therapeutic strategy has gained great success in recent years.1 In the past decade,increasing interest has been drawn towards the antitumor activity of metal/N-heterocyclic carbene(NHC)complexes,which hold great opportunities for the development of novel antitumor metallodrugs.